Loading
NASDAQHealthcareBiotechnology
Latest quote
$10.48
+$0.29 · +2.85%
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Previous close
$10.48
+$0.29 · +2.85%
Regular session · ET · Market data may be delayed.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Day range
Current $10.48
52-week range
Current $10.48
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
87
Deep Value
Sentiment
50
Mixed
Risk
38
Moderate Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Day range
Current $10.48
52-week range
Current $10.48
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 291.85M USD | 203.07M USD | 163.91M USD | 110.25M USD | 49.59M USD |
| Cost of goods sold | 53.41M USD | 36.83M USD | 28.65M USD | 22.63M USD | 13.32M USD |
| Gross profit | 238.43M USD | 166.24M USD | 135.27M USD | 87.61M USD | 36.27M USD |
| Research and development | 31.17M USD | 25.56M USD | 22.34M USD | 20.97M USD | 25.16M USD |
| Selling, general, and administrative | 182.37M USD | 163.48M USD | 146.1M USD | 137.75M USD | 125.72M USD |
| Operating expenses | 213.54M USD | 199.88M USD | 179.28M USD | 169.55M USD | 151.43M USD |
| Interest income | 4.74M USD | 5.32M USD | 4.75M USD | 2.58M USD | 313K USD |
| Interest expense | 29.08M USD | 33.18M USD | 26.61M USD | 14.1M USD | 7.18M USD |
| Depreciation and amortization | 12.16M USD | 12.63M USD | 13.16M USD | 12.67M USD | 1.88M USD |
| Operating income | 24.9M USD | −33.65M USD | −44.01M USD | −81.94M USD | −115.16M USD |
| Net income | 554K USD | −54.84M USD | −62.26M USD | −94.66M USD | −122.73M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM45.76M0.06%78.74B USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI43.83M0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF16.95M0.02%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO16.06M0.12%13.92B USD0.24%$356.78+0.94%
State Street SPDR S&P Pharmaceuticals ETFXPH12.4M2.69%461.57M USD0.35%$64.65+1.60%
Fidelity Enhanced Small Cap ETFFESM11.29M0.17%6.41B USD0.28%$45.46+0.46%
Schwab U.S. Small-Cap ETFSCHA9.9M0.05%21.82B USD0.03%$32.79+0.40%
First Trust Small Cap Growth AlphaDEX FundFYC9.38M0.69%1.35B USD0.70%$115.36+1.35%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHFidelity Enhanced Small Cap ETFFESMSchwab U.S. Small-Cap ETFSCHAFirst Trust Small Cap Growth AlphaDEX FundFYCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
